Businesses

Click here to enlarge

Biocon’s fully integrated business model spans the entire drug value chain, from pre-clinical discovery to clinical development and through to commercialisation. Our businesses in custom research (Syngene), clinical development (Clinigene) and biopharmaceuticals (Biocon) provide multiple revenue streams to balance risk, drive innovation, deliver products and accelerate growth. As we increase the complexity and scope of our own R&D and manufacturing operations, especially in new product discovery and development, we believe our custom and clinical research services will continue to offer important synergies.

Syngene: Pre-Clinical Discovery

Biocon’s custom research organisation, Syngene, offers high value discovery and development services, from target identification and validation to small molecule and library synthesis. With our reputation for meticulous IPR protection, we provide pharmaceutical and biotechnology majors customised solutions in the areas of synthetic chemistry and molecular biology.

Clinigene: Clinical Development

Biocon’s clinical research organisation, Clinigene, specialises in Phase I-IV clinical trials and studies, using well-characterised clinical databases in diabetes, oncology, lipidemia and cardiovascular diseases. We offer these services at our CAP and NABL accredited Central Reference Laboratory and a state-of-the-art Bioavailability and Bioequivalence (BA/BE) Centre.